Business Daily Media

Times Advertising

.

Eisai: Results from LENVIMA (lenvatinib) plus KEYTRUDA (pembrolizumab) Trials

  • Written by ACN Newswire - Press Releases

Eisai: Results from LENVIMA (lenvatinib) plus KEYTRUDA (pembrolizumab) Trials

TOKYO, May 29, 2020 - (JCN Newswire) - Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A. known as MSD outside the United States and Canada, today announced that results from two trials evaluating LENVIMA, an orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai, plus KEYTRUDA, the anti-PD-1 therapy from Merck

Read more //?#

BizCover Brings Australia’s First AI-Based Insurance Quotes to ChatGPT

Australian small business owners can now receive and compare business insurance quotes directly inside ChatGPT, in a move that signals a major shi...

VistaPrint Research Reveals Australian Small Businesses Face a Succession Cliff

With only 16% of retiring small businesses having a succession plan, tens of thousands risk closure as one in three owners nears retirement.  Ne...

Corporate volunteering grows up: how companies are shifting to meaningful, community-led impact

As workplaces settle into the new year and look for ways to strengthen culture, capability and connection, experts say corporate volunteering is e...

The Rise of Mobile-First Venues

Global Hospitality Platform, Tabit, Reveals Five Ways to Maximise Benefits of Mobile-First Systems  As Australian hospitality venues grapple with...

Why the SME is now the primary engine of global cybercrime

For over a decade, the most practical and effective advice we could offer an employee was to spot the typo. It was practical, it was free, and it wo...

Work-life Balance Key to Solving Construction Talent Shortage

New data from leading talent company Randstad Australia shows flexible working and work-life balance could be critical to addressing ongoing talen...